Compugen Ltd
NASDAQ:CGEN

Watchlist Manager
Compugen Ltd Logo
Compugen Ltd
NASDAQ:CGEN
Watchlist
Price: 1.41 USD -2.76% Market Closed
Market Cap: 126.3m USD
Have any thoughts about
Compugen Ltd?
Write Note
CGEN
/
Cash Flow Statement
/
Free Cash Flow

Compugen Ltd
Free Cash Flow

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Compugen Ltd
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Compugen Ltd
NASDAQ:CGEN
Free Cash Flow
$22.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Q
Quoin Pharmaceuticals Ltd
NASDAQ:QNRX
Free Cash Flow
-$8m
CAGR 3-Years
-22%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
B
Biolight Life Sciences Ltd
TASE:BOLT
Free Cash Flow
-₪8.8m
CAGR 3-Years
12%
CAGR 5-Years
-167%
CAGR 10-Years
11%
No Stocks Found

Compugen Ltd
Glance View

Market Cap
126.2m USD
Industry
Life Sciences Tools & Services

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. The firm focuses on infrastructure to discover drug targets and develop therapeutics. The firm is engaged in the research, development and commercialization of therapeutic and product candidates. The firm's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

CGEN Intrinsic Value
1 USD
Overvaluation 29%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Compugen Ltd's Free Cash Flow?
Free Cash Flow
22.3m USD

Based on the financial report for Sep 30, 2024, Compugen Ltd's Free Cash Flow amounts to 22.3m USD.

Back to Top
ALPHA SPREAD
Follow us
Join more than 201,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.